Abstract
This article describes the results of a survey of formulary managers regarding policies and practices relevant to biotechnology medicines. The objectives of the survey were to 1) classify major strategies for controlling current expenditures on biotechnology drugs within managed care plans, 2) categorize their future strategies, and 3) identify the perceived effectiveness of strategies currently in use. Results from the survey suggest that the evolving sophistication of formulary management is a major factor that must be taken into consideration early in clinical research efforts, as well as in the design of clinical trials. Drug Dev.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
